News

Roche And Prothena: Why Moving On Makes Sense
Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...
BioPharma Dive19h
Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug
The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...
PMLive6h
Roche to advance Parkinson’s disease candidate into phase 3 development
Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...
Medical Dialogues12h
Roche to proceed with Phase III development of Prasinezumab in early-stage Parkinson's disease
Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...
Pharmabiz14h
Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease
Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...
Stocktwits on MSN14h
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood
Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...